Healthcare entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention AMT-130, the most common co-covered peer. We currently track 1 Healthcare story that mention uniQure N.V., all published on July 12, 2026.
Last mentioned: Aug 5, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention AMT-130, the most common co-covered peer. We currently track 1 Healthcare story that mention uniQure N.V., all published on July 12, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering uniQure N.V.. Shared-story counts are live from our verified record — not editorial picks.
The FDA’s decision to accept existing AMT-130 clinical data for a BLA submission could fast-track the first disease-modifying treatment for Huntington’s disease, with major implications for healthcare systems, payers, and patients.
Source: insidermonkey.com · finance.yahoo.com
uniQure N.V. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
